Nalaganje...
MET IHC is a Poor Screen for MET Amplification or MET exon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
BACKGROUND: MET amplification and MET exon 14 alterations (METex14) in lung cancers impart sensitivity to MET kinase inhibitors. Fluorescence in situ hybridization (FISH), next-generation sequencing (NGS), and IHC, have been used to evaluate MET dependency. Here, we determined the association of MET...
Shranjeno v:
| izdano v: | J Thorac Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6708730/ https://ncbi.nlm.nih.gov/pubmed/31228623 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2019.06.009 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|